X-ZELL BIOTECH PTE. LTD.
Last Updated: 13 Apr 2026
X ZELL is a global pioneer in multiplexed immunostaining – a patented technology set to revolutionize cancer diagnostics by applying multiple diagnostic antibodies simultaneously to a single specimen.
Our FDA and CE IVD registered next generation cytology platform was specifically designed for minimally invasive cytology samples and processes up to eight antibodies at once – maximizing diagnostic yield while cutting turnaround by over 90%. No complex preparation. No sample wastage.
By combining multiplexing with cutting edge digital imaging, we help laboratories deliver faster, more patient friendly, and personalized care – ready for the digital age.
In May 2025, we previewed our new Cryophore™ range, the world’s first standardized, expert vetted multiplexing panels for routine cytopathology, set to launch globally in Q4 2025.
Headquartered in Singapore, X ZELL operates regional offices in Germany, Thailand, and the US to advance diagnostics and improve patient care worldwide.
Country of registration | Singapore |
Registration number | 201827952Z |
Local SIC | |
Incorporation date | 15 Aug 2018 |
Company age | 7 years 9 months |
Official entity type | Private Limited Company |
No. of officers | 8 |
Contact
Address:
101 CECIL STREET, #10-01, TONG ENG BUILDING, Singapore 069533
Access Key Decision Makers
This is the legal entity page of X-ZELL BIOTECH PTE. LTD.. To access company info, company size, news , key makers’ emails, visit the profile pages above.
Associated business (1)
- X-ZELLView MoreSingaporeX ZELL is a global pioneer in multiplexed immunostaining – a patented technology set to revolutionize cancer diagnostics by applying multiple diagnostic antibodies simultaneously to a single specimen. Our FDA and CE IVD registered next generation cytology platform was specifically designed for minimally invasive cytology samples and processes up to eight antibodies at once – maximizing diagnostic yield while cutting turnaround by over 90%. No complex preparation. No sample wastage. By combining multiplexing with cutting edge digital imaging, we help laboratories deliver faster, more patient friendly, and personalized care – ready for the digital age. In May 2025, we previewed our new Cryophore™ range, the world’s first standardized, expert vetted multiplexing panels for routine cytopathology, set to launch globally in Q4 2025. Headquartered in Singapore, X ZELL operates regional offices in Germany, Thailand, and the US to advance diagnostics and improve patient care worldwide.
This is the legal entity page of X-ZELL BIOTECH PTE. LTD.. To access company info, company size, news, key maker's emails, visit the profile pages above.
Financials
Fiscal/Budgeting Period | October - December |
Revenue | 1m - 5m |
Financial period end date | 31 Dec 2021 |
Share Capital - Ordinary shares | SGD 100 |
Last updated: 13 Apr 2026
* This information is provided to the best of our research ability and we make no warranties for any inaccuracies or omissions.
Discover More Companies
Lookalike companies
* This profile contains information from ACRA Information on Corporate Entities from Accounting and Corporate Regulatory Authority which is made available under the terms of the Singapore Open Data Licence version 1.0. Information and datasets on our website are provided on an “as is” and “as available” basis. This website makes no representations or warranties concerning the datasets, including but not limited to any representation or warranty as to the accuracy, completeness, reliability, continued availability, timeliness, non-infringement, title, quality, or fitness for any particular purpose of the datasets to the fullest extent permitted by the law.
Frequently Asked Questions (FAQ)
- What is the address of X-ZELL BIOTECH PTE. LTD.?
- Where is X-ZELL BIOTECH PTE. LTD.'s headquarter?
- What is X-ZELL BIOTECH PTE. LTD.'s contact number?
- What X-ZELL BIOTECH PTE. LTD.'s spending power?
- Does X-ZELL BIOTECH PTE. LTD. have a presence in the domain it operates in?